Skip to main content
Navigate Up
Sign In

Welcome to the Department of Neurology

Neurology Banner Image
 

Neuroimmunology/MS

Clinical Research



If you think you may qualify for one of these studies, please contact Professional Research Assistant (PRA) below for more information.

Search for: view all

Title (Please click on the title to see approved advertisement) Principal Investigator PRA
A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Subjects with Multiple Sclerosis Immediately Following a Relapse Alvarez, Enrique, MD Mary Cook
303-724-7968
Eligibility and Information
Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological Disorders Alvarez, Enrique, MD Courtney Knapp
MS Hotline
303-724-4644
Please contact PRA for eligibility and information
A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS) Alvarez, Enrique, MD Brittany Kling
MS Hotline
303-724-4644
Please contact PRA for eligibility and information
The Impact of Natalizumab Versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) Subjects (REVEAL) Alvarez, Enrique, MD Nina Bliss
303-724-2197
Eligibility and Information
A Multicenter, Randomized, Addition to Baseline Treatment, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) Bennett, Jeffrey L., MD, PhD Ruth Johnson
303-724-7885
Eligibility and Information
A Phase IV Trial of Neuroprotection with ACTH in Acute Optic Neuritis Bennett, Jeffrey L., MD, PhD Ruth Johnson
303-724-7885
Eligibility and Information
A Phase 2/3, Double-masked, Placebo-controlled Study with Open-Label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Bennett, Jeffrey L., MD, PhD Ruth Johnson
303-724-7885
Eligibility and Information
Collaborative International Research in Clinical and Longitudinal Experience for Neuromyelitis Optica (NMO) Studies (CIRCLES) Bennett, Jeffrey L., MD, PhD Elaine Hsu
303-724-4177
Please contact PRA for eligibility and information
The role of TH40 cell in Multiple Sclerosis and Type 1 Diabetes Corboy, John R., MD Courtney Knapp
MS Hotline
303-724-4644
Please contact PRA for eligibility and information
A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis Corboy, John R., MD Nina Bliss
303-724-2197
Eligibility and Information
A DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF ESTRIOL TREATMENT IN WOMEN WITH MULTIPLE SCLEROSIS: EFFECT ON COGNITION. Corboy, John R., MD Brittany Kling
MS Hotline
303-724-4644
Eligibility and Information
Rocky Mountain MS Center Tissue Bank Corboy, John R., MD Nina Bliss
303-724-2197
Please contact PRA for eligibility and information
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial to Evaluate the Duration of Action of Baclofen ER Capsules (GRS) in Subjects with Spasticity due to Multiple Sclerosis (MS) Corboy, John R., MD Nicola Haakonsen
MS Hotline
303-724-4644
Eligibility and Information
Vestibular rehabilitation for persons with Multiple Sclerosis: what benefits are possible Jeffrey Hebert, PT, PhD Jeffrey Hebert, PT, PhD Eligibility and Information
A multicenter, open-label phase IV study to evaluate whether a Medication Event Monitoring System (MEMS®) can improve adherence to Tecfidera® (delayed-release dimethyl fumarate) treatment in multiple sclerosis patients Miravalle, Augusto A., MD Courtney Knapp
303-724-5439
Eligibility and Information
Improving bladder care for patients with Multiple Sclerosis. Developing a systematic approach for the assessment and diagnosis of neurogenic bladder in Multiple Sclerosis (MS) patients will result in improved bladder care and health related outcomes Miravalle, Augusto A., MD Kawonas Jenkins
MS Hotline
303-724-4644
Please contact PRA for eligibility and information
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical Atrophy Rates and Patient Reported Outcomes (PROs) Miravalle, Augusto A., MD Kawonas Jenkins
MS Hotline
303-724-4644
Please contact PRA for eligibility and information
Comparative Effectiveness of Long Term Gilenya (Fingolimod) versus Copaxone (Glatiramer acetate) On Brain Atrophy Rates, Cognition and Patient Reported Outcomes in Patients with Multiple Sclerosis (MS) Nair, Kavita PhD Eric Engebretson
303-724-8388
Please contact PRA for eligibility and information
Effectiveness Analysis of Natalizumab versus Fingolimod using Patient-Reported Outcomes in Patients with Multiple Sclerosis Nair, Kavita PhD Eric Engebretson
303-724-8388
Please contact PRA for eligibility and information
A Multicenter, Double-Blind, Placebo-Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving TECFIDERA® (Dimethyl Fumarate) Delayed-Release Capsules Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-6351
Eligibility and Information
Cross-Sectional Study of MSDx Complex-1 Association with Gadolinium Enhancing Lesions in Relapsing-Remitting Multiple Sclerosis Schreiner, Teri L., MD, MPH Kawonas Jenkins
MS Hotline
303-724-4644
Eligibility and Information
Medication Adherence in Pediatric Multiple Sclerosis Schreiner, Teri L., MD, MPH Kawonas Jenkins
MS Hotline
303-724-4644
Please contact PRA for eligibility and information
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) Schreiner, Teri L., MD, MPH Nicola Haakonsen
MS Hotline
303-724-4644
Eligibility and Information
Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis Schreiner, Teri L., MD, MPH Ildiko Torok
MS Hotline
303-724-4644
Please contact PRA for eligibility and information
Pediatric Multiple Sclerosis and other Demyelinating Diseases Database (PeMSDD Database) Schreiner, Teri L., MD, MPH Ildiko Torok
MS Hotline
303-724-4644
Please contact PRA for eligibility and information
Two-year, Double-blind, Randomzied, Multicenter, Active-controlled Study to Evaluate Safety and Efficacy of Oral Fingolimod Versus Interferon Beta-1a i.m. in Pediatric Patients With Multiple Sclerosis Schreiner, Teri L., MD, MPH Brittany Kling
MS Hotline
303-724-4644
Eligibility and Information
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients with Primary Progressive Multiple Sclerosis (PPMS) Vollmer, Timothy L., MD Kawonas Jenkins
MS Hotline
303-724-4644
Eligibility and Information
Determining if B cell-astrocyte interactions initiate CNS pathology in Multiple Sclerosis Vollmer, Timothy L., MD
Wendy Macklin, MD
Courtney Knapp
MS Hotline
303-724-4644
Please contact PRA for eligibility and information
Exploring the mechanism of action of laquinimod on B lymphocytes in astrocytes in multiple sclerosis Vollmer, Timothy L., MD
Wendy Macklin, MD
Courtney Knapp
MS Hotline
303-724-4644
Please contact PRA for eligibility and information